Trial Profile
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Zilovertamab (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oncternal Therapeutics, Inc.
- 17 Apr 2023 Planned End Date changed from 30 Apr 2027 to 30 Aug 2024.
- 17 Apr 2023 Planned primary completion date changed from 30 Mar 2025 to 30 Aug 2024.
- 17 Apr 2023 Status changed from recruiting to active, no longer recruiting.